Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Introduction: This study evaluates the quality and diagnostic accuracy of Magnetic Resonance Imaging (MRI) radiomics-based prediction of epidermal growth factor receptor (EGFR) mutation status in non-small cell lung cancer (NSCLC) patients with brain metastasis.
Methods: Six databases (PubMed, Embase, Web of Science, Cochrane Library, Scopus, and IEEE Xplore) were systematically searched up to June 2025. Quality was assessed using the Quality Assessment of Diagnostic Accuracy Studies 2 (QUADAS-2) tool and Radiomics Quality Score (RQS). The predictive performance of MRI radiomics was quantitatively analyzed by pooling sensitivity (SEN), specificity (SPE), positive/negative likelihood ratios (PLR/NLR), diagnostic odds ratio (DOR), and area under the curve (AUC).
Results: 15 studies were included in the systematic review, of which 11 reported sufficient data for meta-analysis (10 training cohorts and 7 validation cohorts). QUADAS-2 indicated that the overall quality of the studies was considered acceptable. The mean RQS score of the included studies was 14.47 (40.19 % of the maximum). Training cohorts achieved the pooled sensitivity, specificity, PLR, NLR, DOR and AUC of MRI-based radiomics for predicting EGFR mutation status were 0.82 [95 % CI: 0.75-0.87], 0.85 [95 % CI: 0.77-0.90], 6.69 [95 % CI: 3.53-12.69], 0.13 [95 % CI: 0.06-0.18], 52.79 [95 % CI: 14.90-187.03], and 0.94 [95 % CI: 0.92-0.96], respectively. For the validation cohorts, these values were 0.77 [95 % CI: 0.69-0.84], 0.83 [95 % CI: 0.78-0.88], 4.64 [95 % CI: 3.45-6.25], 0.27 [95 % CI: 0.20-0.38], 16.69 [95 % CI: 9.85-29.19], and 0.85 [95 % CI: 0.81-0.88].
Conclusion: MRI radiomics-based models may be useful in predicting the EGFR mutation status in patients with brain metastases from NSCLC. However, the analysis revealed limitations including the retrospective design of most studies, geographic bias, and relatively low methodological quality.
Implications For Practice: MRI radiomics may offer a promising non-invasive diagnostic approach for clinical use, providing valuable insights to guide clinical decision-making before obtaining pathological results.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.radi.2025.103113 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Not all type of lepidic pattern is useful for distinguishing whether metachronous multiple lung adenocarcinomas are separate primary lung cancers.
Pathol Res Pract
September 2025
Department of Pathology, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, China. Electronic address:
Our research aims to ascertain the value of precursor and outgrowth lepidic in aiding the confirmation of multiple lung adenocarcinomas as separate primary lung cancers (SPLC). A total of 151 patients with metachronous multiple invasive adenocarcinomas were included in this study. Driver mutation tests（at least five genes: EGFR, ALK, KRAS, BRAF, and ROS1） were conducted on 302 tumors collected from 151 patients.
View Article and Find Full Text PDFIdentification of Targetable Mutations in Ovarian Cancer.
JCO Precis Oncol
September 2025
Division of Hematology and Oncology, University of California Los Angeles, Los Angeles, CA.
Purpose: mutations are classically seen in non-small cell lung cancers (NSCLCs), and EGFR-directed inhibitors have changed the therapeutic landscape in patients with -mutated NSCLC. The real-world prevalence of -mutated ovarian cancers has not been previously described. We aim to determine the prevalence of pathogenic or likely pathogenic mutations in ovarian cancer and describe a case of -mutated metastatic ovarian cancer with a durable response to osimertinib, an EGFR-directed targeted therapy.
View Article and Find Full Text PDFIntegrative profiling of lung cancer biomarkers EGFR, ALK, KRAS, and PD-1 with emphasis on nanomaterials-assisted immunomodulation and targeted therapy.
Front Immunol
September 2025
Department of Thoracic Surgery, Shenzhen People's Hospital (The First Affiliated Hospital, Southern University of Science and Technology; The Second Clinical Medical College, Jinan University), Shenzhen, Guangdong, China.
Background: Lung cancer remains the leading cause of cancer-related mortality globally, primarily due to late-stage diagnosis, molecular heterogeneity, and therapy resistance. Key biomarkers such as EGFR, ALK, KRAS, and PD-1 have revolutionized precision oncology; however, comprehensive structural and clinical validation of these targets is crucial to enhance therapeutic efficacy.
Methods: Protein sequences for EGFR, ALK, KRAS, and PD-1 were retrieved from UniProt and modeled using SWISS-MODEL to generate high-confidence 3D structures.
Multicenter Development of a Clinical-Molecular Nomogram for Predicting Survival in Lung Cancer Brain Metastasis Patients.
Cancer Manag Res
September 2025
The School of Clinical Medicine, Fujian Medical University, Fuzhou, Fujian, People's Republic of China.
Background: Lung cancer brain metastasis (LCBM) accounts for 40-50% of intracranial malignancies, with emerging evidence of alternative metastatic pathways circumventing the blood-brain barrier. Existing prognostic models lack validation in Asian populations and molecular stratification. This multicenter study aimed to develop a clinical nomogram integrating clinicopathological and molecular determinants for personalized LCBM management.
View Article and Find Full Text PDFExceptional Response to Immunotherapy-based Treatment in Compound -Mutated Oligometastatic Pulmonary Sarcomatoid Carcinoma: A Case Report.
J Immunother Precis Oncol
August 2025
Department of Medical Oncology, Sir H N Reliance Foundation Hospital and Research Centre, Mumbai, India.
Pulmonary sarcomatoid carcinoma (PSC) is a rare and aggressive subtype of non-small cell lung cancer (NSCLC) with limited treatment options and poor prognosis. mutations generally respond to tyrosine kinase inhibitors (TKIs)-based targeted therapy but are typically associated with resistance to immunotherapy. We report a case of oligometastatic PSC harboring compound mutations (p.
View Article and Find Full Text PDF